Clover Health Swings to Profit and Raises the Bar for 2026 — But Can a $2.3 Billion Insurer Grow Into Its Valuation?

Shares of Clover Health surged 11.6% to $4.62 after the Medicare Advantage insurer posted a blowout second quarter, swinging to its second consecutive profit and raising full-year targets across the board. For a company that burned cash for years, the question now is whether rapid membership growth and tightening costs can justify a stock that already prices in substantial improvement.

- 56% Revenue Growth and a Meaningful Earnings Beat Signal the Growth Engine Is Working. Revenue hit $743.2 million, up 55.6% year-over-year, beating Wall Street's $728.2 million estimate by 2%.

Earnings came in at $0.07 per share, more than double the $0.03 consensus.

The fuel: Medicare Advantage membership rose 48% year-over-year to 157,000. That kind of enrollment velocity is rare in a mature insurance market, and it translates directly into premium dollars.

- Raised Guidance Tells the Street Management Sees No Slowdown. Clover lifted its full-year revenue outlook to $2.96 billion at the midpoint, up from $2.87 billion — a 3.3% increase , coming in 1.7% above analysts' estimates.

The company also raised targets for gross profit, adjusted EBITDA, and GAAP net income.

Through the first half alone, Clover has already booked $55 million in GAAP net income and $81 million in adjusted EBITDA.

- A 4.5-Star Rating Unlocks Real Financial Advantages for 2027. Management highlighted a 4.5-star quality rating from Medicare for 2027 , a government scorecard that determines bonus payments. Higher stars mean the government pays Clover more per member, giving the company room to offer richer benefits or pocket wider margins — CEO Andrew Toy said the company is enhancing supplemental benefits like food and transportation for 2027, using clinical data to design plans that attract and retain members while staying financially sustainable.

- Insiders Are Selling, and the Valuation Isn't Cheap. Over the past six months, insiders made 20 trades — all of them sales, zero purchases.

Many are characterized as tax-related "sell to cover" transactions on vesting stock. Still, the optics matter. At a $2.33 billion market cap and just $443 million in cash with no debt , the balance sheet is solid — but intense Medicare Advantage competition could pressure future growth. The turnaround is real; whether the stock has already priced it in is the harder call.